Here's Why Tonghua Golden-Horse Pharmaceutical Industry CoLtd (SZSE:000766) Has Caught The Eye Of Investors
Here's Why Tonghua Golden-Horse Pharmaceutical Industry CoLtd (SZSE:000766) Has Caught The Eye Of Investors
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. But the reality is that when a company loses money each year, for long enough, its investors will usually take their share of those losses. A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up.
許多投資者,尤其是那些缺乏經驗的投資者,常常會購買那些有好故事的公司的股票,即使這些公司處於虧損狀態。但現實情況是,當一家公司每年都虧損,持續時間足夠長時,其投資者通常會承受這些損失。一家虧損的公司還沒有能力證明其盈利能力,最終外部資本的流入可能會枯竭。
If this kind of company isn't your style, you like companies that generate revenue, and even earn profits, then you may well be interested in Tonghua Golden-Horse Pharmaceutical Industry CoLtd (SZSE:000766). Even if this company is fairly valued by the market, investors would agree that generating consistent profits will continue to provide Tonghua Golden-Horse Pharmaceutical Industry CoLtd with the means to add long-term value to shareholders.
如果這種公司不符合您的風格,您喜歡能產生營業收入甚至盈利的公司,那麼您可能對通化金馬製藥股份有限公司(SZSE:000766)感興趣。即使這家公司被市場合理定價,投資者仍然會同意,持續盈利將繼續爲通化金馬製藥股份有限公司提供爲股東增加長期價值的手段。
How Fast Is Tonghua Golden-Horse Pharmaceutical Industry CoLtd Growing Its Earnings Per Share?
通化金馬製藥股份有限公司每股收益增長有多快?
In the last three years Tonghua Golden-Horse Pharmaceutical Industry CoLtd's earnings per share took off; so much so that it's a bit disingenuous to use these figures to try and deduce long term estimates. As a result, we'll zoom in on growth over the last year, instead. Tonghua Golden-Horse Pharmaceutical Industry CoLtd's EPS shot up from CN¥0.033 to CN¥0.047; a result that's bound to keep shareholders happy. That's a impressive gain of 42%.
在過去三年中,通化金馬製藥股份有限公司的每股收益大幅增長;這些數據在嘗試推測長期預測時有點不誠實。因此,我們將把重點放在過去一年的增長上。通化金馬製藥股份有限公司的每股收益從CN¥0.033增加到CN¥0.047;這個結果必將使股東們感到高興。這是一個令人印象深刻的增長,達到了42%。
One way to double-check a company's growth is to look at how its revenue, and earnings before interest and tax (EBIT) margins are changing. Tonghua Golden-Horse Pharmaceutical Industry CoLtd's EBIT margins have actually improved by 2.5 percentage points in the last year, to reach 11%, but, on the flip side, revenue was down 7.4%. While not disastrous, these figures could be better.
檢驗一家公司增長的一種方法是看其營業收入和利潤(利息和稅前利潤)的變化。通化金馬製藥股份有限公司的利潤(利息和稅前利潤)率在過去一年實際上提高了2.5個百分點,達到11%,但反過來,營業收入下降了7.4%。雖然並非災難性,但這些數據可以更好。
The chart below shows how the company's bottom and top lines have progressed over time. Click on the chart to see the exact numbers.
下面的表格顯示了公司的營收和淨利潤如何隨着時間的推移的變化。點擊圖表可以查看準確的數字。
While profitability drives the upside, prudent investors always check the balance sheet, too.
儘管利潤帶來上行動能,但審慎投資者也應檢查資產負債表。
Are Tonghua Golden-Horse Pharmaceutical Industry CoLtd Insiders Aligned With All Shareholders?
通化金馬藥業有限公司內部人員與所有股東保持一致嗎?
It should give investors a sense of security owning shares in a company if insiders also own shares, creating a close alignment their interests. Shareholders will be pleased by the fact that insiders own Tonghua Golden-Horse Pharmaceutical Industry CoLtd shares worth a considerable sum. We note that their impressive stake in the company is worth CN¥3.4b. That equates to 27% of the company, making insiders powerful and aligned with other shareholders. Very encouraging.
如果內部人員也持有股份,這會給投資者在公司擁有股份的安全感,從而使他們的利益得以密切對齊。股東將對內部人員持有通化金馬藥業有限公司股份達數億元人民幣的事實感到滿意。我們注意到,他們持有公司的令人印象深刻股份價值34億元人民幣。這相當於公司的27%,使內部人員與其他股東保持強大並保持一致。非常鼓舞人心。
Is Tonghua Golden-Horse Pharmaceutical Industry CoLtd Worth Keeping An Eye On?
通化金馬藥業有限公司值得密切關注嗎?
For growth investors, Tonghua Golden-Horse Pharmaceutical Industry CoLtd's raw rate of earnings growth is a beacon in the night. With EPS growth rates like that, it's hardly surprising to see company higher-ups place confidence in the company through continuing to hold a significant investment. Fast growth and confident insiders should be enough to warrant further research, so it would seem that it's a good stock to follow. Still, you should learn about the 1 warning sign we've spotted with Tonghua Golden-Horse Pharmaceutical Industry CoLtd.
對於成長投資者來說,通化金馬藥業有限公司的每股收益增長率是黑夜中的燈塔。有這樣的每股收益增長率,看到公司高層通過繼續持有大量投資對公司保持信心並不奇怪。快速增長和有信心的內部人員應足以值得進一步研究,因此似乎這是一隻值得關注的優質股票。然而,您應該了解我們發現的通化金馬藥業有限公司的一個警示標誌。
While opting for stocks without growing earnings and absent insider buying can yield results, for investors valuing these key metrics, here is a carefully selected list of companies in CN with promising growth potential and insider confidence.
雖然不選取增長收益和缺少內部人買入的股票可能會產生效果,但是對於重視這些關鍵指標的投資者,這裏是一份精心挑選的具有巨大增長潛力和內部人信心的CN公司列表。
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
請注意,本文討論的內部交易是指在相關司法管轄區中報告的交易。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。